Eli Lilly won’t be making any mega pharmaceutical deals, Chairman and Chief Executive John Lechleiter said Wednesday.
While the environment is good for deals, with interest rates low and companies flush with cash, Lechleiter told WSJ today that Eli Lilly will be steering clear of any large deals and will not be diversifying itself.
